Short Interest Worth Watching: What Will Happen to Cleveland Biolabs Incorporated (NASDAQ:CBLI) Next? The Stock Has Decline in Shorts

November 28, 2016 - By Linda Rogers   ·   0 Comments

Short Interest Worth Watching: What Will Happen to Cleveland Biolabs Incorporated (NASDAQ:CBLI) Next? The Stock Has Decline in Shorts

The stock of Cleveland Biolabs Incorporated (NASDAQ:CBLI) registered a decrease of 0.96% in short interest. CBLI’s total short interest was 165,800 shares in November as published by FINRA. Its down 0.96% from 167,400 shares, reported previously. With 31,900 shares average volume, it will take short sellers 5 days to cover their CBLI’s short positions. The short interest to Cleveland Biolabs Incorporated’s float is 6.78%. About 21,929 shares traded hands. Cleveland BioLabs, Inc. (NASDAQ:CBLI) has declined 32.77% since April 25, 2016 and is downtrending. It has underperformed by 38.78% the S&P500.

Cleveland BioLabs, Inc. is a biopharmaceutical company. The company has a market cap of $17.61 million. The Company’s programs are focused developing approaches to activate the immune system and address serious medical needs. It currently has negative earnings. The Company’s platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology.

Insitutional Activity: The institutional sentiment increased to 1.25 in Q2 2016. Its up 0.82, from 0.43 in 2016Q1. The ratio improved, as 5 funds sold all Cleveland BioLabs, Inc. shares owned while 2 reduced positions. 0 funds bought stakes while 3 increased positions. They now own 406,408 shares or 4.11% less from 423,822 shares in 2016Q1.
Blackrock Advsr Limited Liability Company has 0% invested in the company for 2,800 shares. Us National Bank De reported 100 shares or 0% of all its holdings. Vanguard Grp last reported 0% of its portfolio in the stock. Winfield Assoc last reported 0% of its portfolio in the stock. Geode Management Llc has invested 0% of its portfolio in Cleveland BioLabs, Inc. (NASDAQ:CBLI). Pine River Capital Management Lp holds 150,000 shares or 0% of its portfolio. Deutsche Fincl Bank Ag reported 87 shares or 0% of all its holdings. Group Inc One Trading L P accumulated 0% or 68 shares. Blackrock Fund Advsrs holds 0% or 684 shares in its portfolio. Morgan Stanley, a New York-based fund reported 1,255 shares. The North Carolina-based Retail Bank Of America Corporation De has invested 0% in Cleveland BioLabs, Inc. (NASDAQ:CBLI). Bancshares Of Montreal Can holds 0% of its portfolio in Cleveland BioLabs, Inc. (NASDAQ:CBLI) for 31 shares. Manufacturers Life Insur The has invested 0% of its portfolio in Cleveland BioLabs, Inc. (NASDAQ:CBLI). Cowen Gru last reported 109,375 shares in the company. Ladenburg Thalmann Financial Services last reported 36,643 shares in the company.

CBLI Company Profile

Cleveland BioLabs, Inc. (CBLI), incorporated on June 5, 2003, is a biopharmaceutical company. The Company’s programs are focused developing approaches to activate the immune system and address serious medical needs. The Company’s platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. CBLI’s advanced product candidate is entolimod, an immuno-stimulatory agent, which the Company is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. It also has an additional clinical-stage program and multiple projects in different stages of preclinical drug development. The Company’s products include Entolimod, CBLB612 and Mobilan.

More notable recent Cleveland BioLabs, Inc. (NASDAQ:CBLI) news were published by: Quotes.Wsj.com which released: “News Cleveland BioLabs Inc.CBLI” on February 11, 2011, also Marketwatch.com with their article: “Cleveland BioLabs Reports Second Quarter 2016 Financial Results and …” published on August 15, 2016, Thestreet.com published: “Cleveland BioLabs (CBLI) Stock Spikes on $25 Million Equity Financing Agreement” on June 25, 2015. More interesting news about Cleveland BioLabs, Inc. (NASDAQ:CBLI) were released by: Medgadget.com and their article: “Cleveland BioLabs, Inc. Pipeline Reviews and Clinical Trail Assessment 2016 …” published on September 13, 2016 as well as Streetinsider.com‘s news article titled: “Cleveland Biolabs (CBLI) Announces $1.1M JWMRP Contract Modification with U.S. DoD” with publication date: October 11, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Linda Rogers


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>